{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"35"}],"units":"Participants"}],"description":"The primary safety variable was to determine the incidence of DLTs in subjects with relapsed or relapsed/refractory multiple myeloma treated with BT062.","groups":[{"description":"40 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG000","title":"BT062 40 mg/m²"},{"description":"50 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG001","title":"BT062 50 mg/m²"},{"description":"65 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG002","title":"BT062 65 mg/m²"},{"description":"80 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG003","title":"BT062 80 mg/m²"},{"description":"100 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG004","title":"BT062 100 mg/m²"},{"description":"120 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG005","title":"BT062 120 mg/m²"},{"description":"140 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG006","title":"BT062 140 mg/m²"},{"description":"160 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG007","title":"BT062 160 mg/m²"},{"description":"BT062 administration (all dose levels)","id":"OG008","title":"Total"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety population included all subjects who were enrolled and received at least\n\n1 dose of BT062 (n = 35).","reportingStatus":"POSTED","timeFrame":"Starting with first study drug administration until 30-day follow-up visit (average 4.99 months)","title":"Dose Limiting Toxicities (DLT) - Number of Participants With at Least 1 DLT","type":"PRIMARY","unitOfMeasure":"Participants"}